| Name | Title | Contact Details |
|---|
resTORbio, Inc. is a clinical stage company, developing medicines to treat aging-related diseases and conditions. resTORbio`s lead program targets the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat aging-related diseases and conditions. Initially, resTORbio is focused on developing medicines that address conditions caused by immunosenescence, the decline in immune function due to aging. resTORbio has initiated a Phase 2b trial for its lead product candidate, RTB101, evaluating its potential to reduce the incidence of respiratory tract infections (RTI) in elderly individuals at increased risk of RTI-related morbidity and mortality. resTORbio`s lead program is built upon two Phase 2a clinical studies demonstrating promising safety and efficacy results in almost 500 elderly individuals.
WuXi NextCODE is a global biotechnology company harnessing genomic big data to propel drug discovery, clinical diagnoses, population health, and precision medicine.
Ortho-McNeil Pharmaceutical, Inc. is a Raritan, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Tri-Source Pharma is a pharmaceutical manufacturer/distributor operating in both the human and animal health care industries.
Pacificord is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.